Visual analog scale has comparable validity for perennial allergic, nonallergic rhinitis

The visual analog scale (VAS) demonstrates comparable validity for perennial allergic rhinitis (PAR) and nonallergic rhinitis ...
MedPage Today

Higher-Dose Aflibercept Similar to Standard Dose in Severe AMD Variant

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...
Seeking Alpha

Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away

Ideaya Biosciences, Inc. is a precision oncology company with a robust pipeline, highlighted by lead asset darovasertib for uveal melanoma. IDYA's darovasertib shows promising Phase 2 results and ...
Morningstar

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial ...
ophthalmologytimes

Positive phase 2 data for neoadjuvant darovasertib offers hope for unmet need in uveal melanoma

The Phase 2 OptimUM-09 trial shows promising results for uveal melanoma, addressing the lack of approved systemic therapies. Significant tumor size reduction and improved visual acuity were observed ...
Frontiers

HK-OxVPS: an adaptation of the Oxford Visual Perception Screen for the Cantonese speaking population in Hong Kong

The Oxford Visual Perception Screen (OxVPS) is a screening tool recently developed for visual perception deficits that occur after a stroke, such as difficulties in recognizing objects, faces, and ...
Morningstar

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage 57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased ...
Nasdaq

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today presented positive clinical data from their ...
The New York Times

Why is the SCORE Act in limbo? College sports’ long wait for help from Congress continues

A flurry of activity in Washington D.C. in July suggested lawmakers would return from summer recess ready to move on a bill designed to potentially bring order to college sports, taking meaningful ...
The Lancet

Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial

gMolecular Surgery Lab, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Palo Alto, CA 94303, USA Stargardt disease (SD) is an inherited degenerative retinal disease ...
bjo.bmj

Retrospective multicentre study on functional vision score calculation using automated perimeter

Background/aims This study aimed to develop a predictive equation for Functional Field Score (FFS), a component of the Functional Vision Score (FVS) derived from binocular Esterman test results via ...